11:20 AM EDT, 06/26/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target price to $12 from $7, based on our DCF analysis, and change our recommendation on shares of TXG to Hold from Sell. We widen our 2025 adjusted LPS view to $-0.99 from -$0.56 and our 2026 adjusted LPS estimate to -$0.91 from -$0.65. Based on a New York Times article yesterday, the NIH issued an internal memo pausing cancellations of medical research grants, which brings temporary relief to a number of life science tools and services companies in our U.S. coverage, in our view. While the news seems temporary, we think this helps improve investor sentiment, especially for companies such as TXG, which generate more than 50% of their revenues in the U.S. and have large exposure to government and academic end markets domestically. Yet, we prefer to remain on the sidelines as we see a number of uncertainties in the global macroeconomic environment that may continue to put pressure on the company's performance.